Mint Explainer | How the NPPA plans to rein in cancer drug prices
The remaining market, worth over ₹10,250 crore, comprises non-scheduled cancer drugs. The NPPA analysis showed that non-scheduled cancer drugs carried an average trade markup of approximately 170%, rocketing up to 700% in certain cases, alongside steep price variations across hospital pharmacies, retail shops, and e-pharmacy channels.
